Introduction
============

Astrocyte \[Ca^2+^\]~i~ transients have been shown to directly alter diameters of cerebral arterioles in experiments using either direct astrocyte stimulation or calcium uncaging in astrocytes of juvenile ([@B58]; [@B24]; [@B13]), or adult animals ([@B45]). However, several laboratories have published contradictory evidence on whether, in adult animals, astrocyte \[Ca^2+^\]~i~ signaling is evoked by synaptic activity leading to neurovascular coupling ([@B58]; [@B34]; [@B38]; [@B23]; [@B32]) or not ([@B29]; [@B46]; [@B5]). More recently, astrocyte \[Ca^2+^\]~i~ was shown to modify basal arteriole tone in adult animals ([@B37]). Therefore, it is still poorly understood when, how, and under what conditions, astrocyte \[Ca^2+^\]~i~ signaling contributes to the regulation of cerebral blood flow (CBF).

In this work, we investigated the mechanisms underlying CBF responses to increased blood CO~2~ concentrations (hypercapnia) and the potential contribution of astrocytes to those CBF responses. Arterial CO~2~ has a potent effect on CBF, with a 1 mmHg variation eliciting a 3%--4% CBF change ([@B15]). However, the mechanism coupling a change in CO~2~ to a change in CBF is incompletely understood. There are parallels between the vasoactive signals generated by astrocytes and those underlying hypercapnia-evoked CBF responses. Astrocytes have been shown to directly modify arteriole diameter when their intracellular \[Ca^2+^\]~i~ increases, activating astrocytic phospholipase A~2~ (PLA~2~) ([@B16]) and thereby generating arachidonic acid (AA) and several vasoactive metabolites including PgE~2~, which causes vasodilation ([@B58]; [@B45]; [@B13]; [@B3]). In addition to their roles in neurovascular coupling, both PgE~2~ ([@B54]; [@B53]) and cyclooxygenase-1 (COX-1) activity ([@B28]) are involved in increasing CBF during hypercapnia. We examined the potential link between astrocytes and increased CBF during hypercapnia because astrocytes express the enzymes that are involved in synthesizing PgE~2~ from AA during hypercapnia-induced CBF changes ([@B28]). For example, mRNA for both COX-1 and microsomal prostaglandin E synthase-1 (mPgES-1) are reported in transcriptome studies to be highly expressed in astrocytes but not neurons (e.g., ptgs1, also known as COX-1, is 15-fold higher in astrocytes than in neurons) ([@B8]; [@B57]). Astrocytes are immunoreactive for both the enzyme proteins COX-1 ([@B45]; [@B13]) and mPgES-1 (see [Fig. 3](#F3){ref-type="fig"}*A* and [@B44]). mPgES-1, the form of prostaglandin E synthase expressed in astrocytes, requires the cofactor glutathione (GSH) ([@B18]; [@B25]) that is present in high levels in astrocytes (see [Fig. 3](#F3){ref-type="fig"}*B* and [@B43]; [@B6]; [@B36]). We investigated whether hypercapnia can evoke an increase in astrocyte \[Ca^2+^\]~i~ *in vivo* and, if so, whether this results in activation of a PgE~2~-mediated vasodilation. In doing so, we demonstrate a novel, GSH-dependent mechanism of CBF regulation, which involves astrocytes and the GSH-sensitive release of PgE~2~.

Materials and Methods
=====================

### Slice preparation

Four hundred μm hippocampal-neocortical slices were prepared from male and female juvenile (postnatal age 16--21 d) Sprague Dawley rats. Treatment of animals was approved by the University of British Columbia Animal Care and Use Committee. As previously described ([@B13]), rats were anesthetized with halothane, decapitated, and the brains removed into ice-cold slicing solution containing the following (in m[m]{.smallcaps}): 2.5 KCl, 26 NaHCO~3~, 0.5 CaCl~2~, 10 MgSO~4~, 1.25 NaH~2~PO~4~, 10 glucose, 230 sucrose, saturated with 95% O~2~/5% CO~2~. The 400 μm transverse hemi-sections were incubated at 32°C-34°C in aCSF containing the following (in m[m]{.smallcaps}): 126 NaCl, 2.5 KCl, 26 NaHCO~3~, 2.0 CaCl~2~, 2.0 MgCl~2~, 1.25 NaH~2~PO~4~, 10 glucose, saturated with 95% O~2~/5% CO~2~ for 60 min. For experiments, slices were at 22°C-24°C, aCSF was saturated with 20% O~2~/5% CO~2~, balanced N~2~, and perfused at ∼2 ml/min. Healthy slices can be maintained in 20% O~2~, which provides a pO~2~ at the low end of the physiological range ([@B13]). Astrocytes were loaded with the caged IP~3~ compound, NV-IP~3~/AM (5 μg/ml), and/or the Ca^2+^ indicator rhod-2/AM (10 μ[m]{.smallcaps}, Invitrogen) as previously described ([@B24]; [@B13]). Slices were loaded with monochlorobimane (MCB, Fluka) in the dark at room temperature for 30 min as previously described ([@B36]).

### Two-photon imaging and uncaging in acute brain slices

A two-photon laser-scanning microscope (Zeiss LSM510-Axioskop-2 fitted with a 40×-W/1.0 numerical aperture objective lens) coupled to a Chameleon ultra II Ti:sapphire laser (∼140 fs pulses 80 MHz, Coherent) provided excitation of rhod-2 and was used to uncage IP~3~. Images were acquired 50--100 μm below the slice surface. Rhod-2 fluorescence imaging and two-photon uncaging were performed using laser settings and emission filters as previously described ([@B13]). MCB was excited at 780 nm and detected with a PMT at 512--562 nm as previously described ([@B36]). Arterioles (defined as vessels with diameter \>10 μm, surrounded by a visible layer of smooth muscle cells) were imaged by acquiring the transmitted laser light and using IR-DIC optics.

### Glutathione and PgE~2~ measurements

Protocols in suppliers\' instructions were followed for the PgE~2~ ELISA and glutathione assays. When measuring PgE~2~ release from acute brain slices, TTX (1 μ[m]{.smallcaps}, Alamone Labs) was added to dampen neuronal activation. PgE~2~ release from acute brain slices was measured using a Specific Parameter PgE~2~ ELISA kit (R&D systems). Measurements of tissue glutathione levels were made using a specific total glutathione assay kit from either BioVision or Assay Designs.

### Immunohistochemistry

Rats were anesthetized with halothane, given an intraperitoneal injection of urethane (0.5 ml of 30% urethane per 50 g body weight), and perfused with saline (0.9% NaCl in 0.1 [m]{.smallcaps} phosphate buffer) followed by 4% PFA (in 0.1 [m]{.smallcaps} PBS). The brain was extracted, postfixed (10% sucrose in 4% PFA) overnight, and cryoprotected (30% sucrose in PBS) overnight. Using a cryostat, 40 μm serial sections in the horizontal plane were collected throughout the brain. Free-floating sections were blocked with 10% normal goat serum (Jackson ImmunoResearch Laboratories) and 0.4% Triton X-100 in PBS for 1 h and incubated in PBS containing 0.1% Triton X-100 and primary antibodies against PgE~2~ synthase (anti-mPgES-1) ([@B31]; [@B52]) (Agrisera, catalog \#AS03 031, 1:200) as well as an astrocyte phenotypic marker (anti-GFAP ([@B21]) (Sigma, catalog \#G3893, clone \#G-A-5, 1:500) overnight at 4°C. Tissue was rinsed and incubated in AlexaFluor-488 goat anti-mouse and AlexaFluor-546 goat anti-rabbit secondary antibodies (Invitrogen: diluted 1:500 in PBS, 2.5% normal goat serum and 0.4% Triton X-100) for 1.5 h at room temperature. The tissue was rinsed, mounted onto slides, and coverslipped using Fluorsave mounting medium (Calbiochem). Images were acquired with an Olympus Fluoview FV1000 confocal microscope.

### Drugs

trans-ACPD (tACPD), clonidine, norepinephrine (NE; Sigma), and PgE~2~ (Cayman Chemicals) were bath applied for 5--10 min. SC560 (Sigma) was preincubated for 30 min ([@B4]) followed by bath application and buthionine sulfoximine (BSO; Sigma) was preincubated for 2.5 h ([@B43]) followed by bath application throughout the experiment. NV-IP~3~/AM was synthesized by G. Ellis-Davies.

### Animals: *in vivo* blood flow measurements in rats

All procedures were approved by the University of Oxford Ethical Review Committee and complied with the requirements of the Animals (Scientific Procedures) Act, 1986, United Kingdom. Animals were housed in an animal housing facility in a 12 h alternating light:dark cycle with *ad libitum* access to food and water. Male Wistar rats were used (256--367 g).

### Intracerebral injection

For surgical procedures, rats were anesthetized with 4% isoflurane and maintained at 1.5%--2% isoflurane in 30% O~2~ and 70% N~2~. Each rat was placed in a stereotaxic frame and the skull exposed. A burr hole was drilled at 1 mm caudal and 4.2 mm lateral to bregma, and the dura mater was finely dissected away to expose the cortex. Twenty μl of 80 mg/ml BSO ([@B35]) or 0.9% saline was infused by a microinfusion pump at a rate of 2 μl/min into the right whisker barrel cortex at a depth of 2.3 mm from the brain\'s surface. This dose of BSO has previously been shown to adequately reduce GSH within 24 h of administration ([@B35]), and we showed that BSO administered in this way could decrease GSH levels in the ipsilateral cortex by 45%, 24 h after injection (see [Fig. 5](#F5){ref-type="fig"}*C*), and in the ipsilateral striatum by 31% (GSH measured in saline-treated: 0.61 ± 0.03 mM, BSO-treated: 0.42 ± 0.08 mM, *p* = 0.045, *n* = 7 per group, mean ± SEM). After the infusion, bone wax was placed over the burr hole and the wound was closed with 3--0 sutures. Animals recovered for 24 h before assessment of GSH levels (*n* = 7 per group) or evoked blood flow responses (*n* = 6--10 per group).

### Whisker pad stimulation and hypercapnia: *in vivo* blood flow measurements

At 24 h after BSO/saline treatment, animals had their left femoral artery cannulated for blood gas measurement and were tracheotomized and ventilated with 1.25% isoflurane in 30% O~2~ and 70% N~2~. A laser Doppler probe (Perimed) to monitor relative CBF was placed over the right whisker barrel cortex (where the intracerebral injection was made) and bipolar stimulating electrodes were placed in the left whisker pad. For some experiments, a local field potential (LFP) electrode for neuronal activity was also placed on the exposed cortex to monitor neuronal activity. All animals had a steady-state blood gas ([Table 1](#T1){ref-type="table"}) before beginning experiments.

###### 

Blood gases for BSO experiment (Nota Bene blood gases taken 24 h after drug but before hypercapnia and whisker stimulation experiments)[*^a^*](#TF1-1){ref-type="table-fn"}

  Treatment                                 pH            pCO~2~ (mmHg)   pO~2~ (mmHg)
  ----------------------------------------- ------------- --------------- --------------
  Saline                                    7.47 (0.01)   34.5 (2.3)      161 (4)
  BSO[*^b^*](#TF1-2){ref-type="table-fn"}   7.46 (0.01)   35.8 (1.5)      154 (7)

*^a^*Data are mean (SEM).

*^b^*An inhibitor of γ-glutamylcysteine synthetase.

An electrical stimulus (10 Hz, 16 s duration, 1.6 mA, 0.3 ms pulsewidth, 60 s interstimulation interval) to evoke a blood flow response in the right whisker barrel cortex was performed for 10 trials per animal. Following this, animals were exposed to 10% CO~2~ for 30 s at 3 min intervals repeated 4 or 5 times to induce hypercapnic blood flow responses. Animals were killed and the cortex dissected for measurement of GSH levels.

For SC560 experiments, naive rats were anesthetized with isoflurane. Anesthesia was induced with 4% isoflurane and maintained during surgery with 2% isoflurane. During stimulation, anesthesia was maintained with 1.25% isoflurane. Isoflurane was carried in 30% O~2~ and 70% N~2~. Rats had their left femoral artery and vein cannulated, and were also tracheotomized and ventilated. A laser speckle camera (Moor Instruments) was used to monitor relative CBF over a thin skull window over the right whisker barrel cortex while an LFP electrode for neuronal activity was inserted through a burr hole. Bipolar stimulating electrodes were placed in the left whisker pad. Animals had a steady-state blood gas before and after drug administration ([Table 2](#T2){ref-type="table"}). An electrical stimulus (10 Hz, 16 s duration, 1.6 mA, 0.3 ms pulsewidth, 60 s interstimulation interval) to evoke a blood flow response in the right whisker barrel cortex was performed for 10 trials per animal. Following this, animals were exposed to 10% CO~2~ for 30 s at 3 min intervals repeated four times to induce a hypercapnic blood flow response. Animals were then administered 5 mg/kg SC560 or 10% DMSO (vehicle) intravenously. SC560 is a highly lipophilic COX-1 inhibitor and distributes widely into tissues ([@B48]), and this dose was chosen for maximal target efficiency ([@B56]). After 20 min, the effect of COX-1 inhibition on the evoked CBF responses to whisker stimulation and hypercapnia was measured.

###### 

Blood gases for SC560 intravenous experiment (Nota Bene blood gases taken before and after drug administration)[*^a^*](#TF2-1){ref-type="table-fn"}

  Condition   Treatment     pH            pCO~2~ (mmHg)   pO~2~ (mmHg)
  ----------- ------------- ------------- --------------- --------------
  Predrug     DMSO          7.47 (0.01)   33.5 (1.5)      164 (5)
  SC560       7.45 (0.01)   36.8 (1.2)    140 (5)         
  Postdrug    DMSO          7.46 (0.01)   34.1 (0.6)      156 (6)
  SC560       7.45 (0.03)   37.1 (2.1)    140 (5)         

*^a^*Data are mean (SEM).

### Animals: *in vivo* calcium imaging

For *in vivo* experiments, all procedures involving animals were approved by the Danish National Ethics Committee according to the guidelines set forth in the European Council\'s Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes. The 8- to 10-week-old male C57BL/6J mice were used.

### *In vivo* calcium imaging

For experiments involving mice, anesthesia was induced with bolus injections of the α2-adrenergic receptor agonist xylazine (10 mg/kg i.p.) and the NMDA-receptor antagonist ketamine (60 mg/kg i.p.). Anesthesia was maintained during surgery with supplemental doses of ketamine (30 mg/kg/20 min i.p.). Upon completion of all surgical procedures, anesthesia was switched to continuous infusion with α-chloralose (50 mg/kg/h i.v.).

Calcium activity during hypercapnia was measured *in vivo* in eight C57BL/6J mice. A craniotomy over the somatosensory cortex was covered with agarose and partly sealed with a glass coverslip. Oregon Green Bapta-1/AM (OGB; Invitrogen) was dissolved in DMSO and Pluronic F-127 (10%, BASF Global) and diluted in aCSF to yield a final dye concentration of 0.8 m[m]{.smallcaps}. It was mixed with the astrocyte marker sulforhodamine 101 (SR101; Sigma-Aldrich, 100 μ[m]{.smallcaps}) ([@B26]) and was pressure injected (4--6 psi, 4 s) into the somatosensory cortex through a micropipette at a depth of 100--150 μm below the cortical surface. Ca^2+^ imaging was performed using a commercial two-photon microscope (SP5 multiphoton/confocal Laser Scanning Microscope; Leica), and a Mai Tai HP Ti:sapphire laser (Millennia Pro, Spectra Physics) with a 20× 1.0 NA-water-immersion objective (Leica). The excitation wavelength was 820 nm. The emitted light was filtered to retain both red and green light using a TRITC/FITC filter.

The hypercapnia challenge was presented as follows: Following 1 min baseline recording, 10% CO~2~ in air was applied for 30 s and imaging continued for subsequent 4 min. Five trials were performed with 3 min between trials. For each animal, a second field of view was selected and the hypercapnia challenge repeated. Blood gases were taken after each experiment, and all mice had pCO~2~ in the range 30--40 mmHg and pO~2~ in the range 95--130 mmHg.

### Data collection, analysis, and statistics

#### *In vitro* data.

An image (512 × 512 pixels) was collected in 7.86--12.68 s, using 8-line averaging. Measurements of lumen diameter and Ca^2+^ changes were performed offline with Zeiss LSM (version 3.2) software and ImageJ (National Institutes of Health). As previously described ([@B13]), fluorescence signals were defined as *F*/*F*~0~ (%) = \[(*F*~1~ − *B*~1~)/(*F*~0~ − *B*~0~)\]100, where *F*~1~ and *F*~0~ are fluorescence at a given time and the mean fluorescence during the control period, respectively. *B*~1~ and *B*~0~ are the corresponding background fluorescence signals, taken from the neuropil. Pseudo-color images show absolute changes in fluorescence (ImageJ, 16-color linear Lut). Experimental values are mean ± SEM; *n* is the number of experiments conducted or, for calcium changes, number of astrocytes analyzed. Either a two-tailed Student\'s *t* test or a one-way ANOVA with a Newman--Keuls *post hoc* test for comparison between multiple groups was used, and *p* \< 0.05 was considered statistically significant. As these were novel experiments, the effect size was unknown before the experiment. Therefore, sample size estimates were based on our previous experience. Experiments were alternately performed under control or treatment conditions with slices chosen at random for each experiment. Data were excluded from analysis if any of the following occurred during imaging: unstable baseline vessel diameters or astrocyte calcium levels, or movement leading to significant focus changes during the experiment. To perform statistical analysis, data were assumed to be normally distributed.

#### *In vivo* data.

All laser Doppler and LFP data were collected in Spike 2 software, whereas laser speckle data were collected using Moor FLPI software. Quantification of CBF changes and electrophysiology were performed in MATLAB (The MathWorks, version 7.12). To obtain the region of interest (ROI) for calculation of CBF changes using laser speckle imaging, a principal components analysis was used to identify the focal point of the change in response to stimulation. The same region of interest was used within each animal\'s data. Experimental values are the mean ± SEM, and *n* is the number of animals. To perform statistical analysis, data were assumed to be normally distributed. An *F* test was used to compare variances of groups being statistically compared. For CBF data, a one-tailed *t* test with Welch\'s correction (as groups had significantly different variances) was used to compare means between groups. A two-tailed *t* test was used to compare means of groups for both GSH analysis (see [Fig. 5](#F5){ref-type="fig"}*C*) and electrophysiology data in response to whisker pad stimulation (Welch-corrected for SC560 experiment, see [Fig. 6](#F6){ref-type="fig"}*C*). For electrophysiology data collected during hypercapnia challenge experiments, a two-way ANOVA with Bonferroni correction for multiple comparisons was used to compare means between groups. *p* \< 0.05 was considered statistically significant. For experiments involving rats, due to effect sizes being unknown before experiment, sample size estimates were based on previously published sample sizes (e.g., [@B28]). Assignment of animals was alternated between treatment and control groups, and neither experiments nor analysis were blinded. Three animals were excluded from all data analysis (1 for SC560 and 2 for BSO) due to technical problems with experimental equipment.

For *in vivo* calcium imaging, frame size was 256 × 256 pixels (189--207 ms/frame) during recordings. The Ca^2+^ changes were evaluated as the average change in fluorescence relative to baseline levels in ROIs. The ROIs were placed based on morphology over neuronal or astrocytic soma, or neuropil. Because of movement of astrocytes during hypercapnia, within or out of focus, ROIs were evaluated based on the level of SR101 loading in the red channel. If a significant change occurred, the ROI was disregarded in all following assessments. An increase in fluorescence within an ROI was classified as a calcium response if the mean fluorescence value within the period of hypercapnia was \>2 SDs of baseline activity. The delay of the Ca^2+^ response was found by subtracting the signal onset time from the time hypercapnia was introduced to the animal. To estimate response start and termination time, a fit was made to the data and the first- and second-order derivatives were calculated. The response onset time was found by taking the maximum peak of the second order derivative of the fitted data. The duration of the Ca^2+^ response was then found by subtracting the response onset time from the response termination time. The response termination time was defined as the time point when the fitted data went below mean baseline Ca^2+^ levels or the recording ended. Experimental values are expressed as mean ± SEM. A paired *t* test was used for the calcium imaging data, each animal served as its own control. *p* \< 0.05 was accepted as statistically significant. For experiments involving mice, as there have been no previous studies reporting astroglial calcium changes during hypercapnia, it was impossible to estimate an expected value for change in fluorescence or its SD. Hence, no sample size calculation could be performed. However, we expected similar calcium changes to those we observe for low-frequency whisker stimulation, and so sample sizes were based on our previous experiments (6--8 mice). Calcium signals obtained during hypercapnia exceeded an SNR of 4:1, and hypercapnia-induced calcium responses were recorded in every animal tested. As all mice were subjected to hypercapnia, there was no randomization method used. Control measurements of calcium activity (i.e., activity without application of hypercapnia) were taken at random time points during the experiment. Analysis of calcium changes was not blinded, assessment of these changes was based on a MATLAB program, which analyzes the image sequences in an unbiased manner, rather than by visual inspection.

Results
=======

Increased CO~2~ evokes \[Ca^2+^\]~i~ responses in astrocytes *in vivo*
----------------------------------------------------------------------

Elevation of tissue CO~2~ concentration, which can be caused by neuronal metabolism, is known to dilate cerebral blood vessels in a process dependent on PgE~2~ ([@B54]; [@B53]) formation via COX-1 activity ([@B28]). However, the cells that both are responsible for sensing CO~2~ and that also express the enzymes for synthesizing PgE~2~ (COX-1 and PgES) have not been resolved. Astrocytes can produce PgE~2~, but it is unknown whether astrocytes generate \[Ca^2+^\]~i~ signals in response to CO~2~. Therefore, we tested whether an increase in inspired CO~2~ (hypercapnia) *in vivo* evokes astrocyte \[Ca^2+^\]~i~ when it also triggers CBF increases.

Two-photon laser scanning microscopy (2PLSM) *in vivo* was used to examine the simultaneous responses of both neurons and astrocytes to hypercapnia in the intact brain as a first step to investigate which cell type might be the primary sensor of CO~2~ ([Fig. 1](#F1){ref-type="fig"}). Remarkably, we found consistent and significant increases in \[Ca^2+^\]~i~ in the soma and endfeet of astrocytes in cortical layers II/III of mouse ([Fig. 1](#F1){ref-type="fig"}) during the period of hypercapnia. The dramatic increases that we observed in astrocytes were of significantly higher amplitude ([Fig. 1](#F1){ref-type="fig"}*A--C*; *p* \< 0.01) than increases in \[Ca^2+^\]~i~ observed in neuronal soma during the period of hypercapnia. The number of astrocytes with \[Ca^2+^\]~i~ responses was also much greater in hypercapnia compared with the number showing spontaneous calcium activity (control time period: [Fig. 1](#F1){ref-type="fig"}*D*; *p* \< 0.01). Although neurons could display increased \[Ca^2+^\]~i~ during hypercapnia, with onset times within seconds ([Fig. 1](#F1){ref-type="fig"}*B*,*C*,*E*), there was no significant difference in the number of neurons with \[Ca^2+^\]~i~ responses during hypercapnia compared with the number showing spontaneous calcium activity (control time period: [Fig. 1](#F1){ref-type="fig"}*D*). Measurements taken in the neuropil where there were no defined cell bodies, and it is difficult to separate signals in fine astrocyte processes from neuronal processes did not show correlated changes in \[Ca^2+^\]~i~ signals during hypercapnia ([Fig. 1](#F1){ref-type="fig"}*D*). The astrocyte \[Ca^2+^\]~i~ responses ([Fig. 1](#F1){ref-type="fig"}*B,E*,*F*) appear to occur within a similar timescale as the increased CBF evoked by hypercapnia (as measured by laser speckle contrast imaging and laser Doppler flowmetry in rat; see [Fig. 5](#F5){ref-type="fig"}*A*, *D*, respectively). During hypercapnia, an increased number of astrocyte soma ([Fig. 1](#F1){ref-type="fig"}*D*) displayed increased \[Ca^2+^\]~i~ with onsets within seconds ([Fig. 1](#F1){ref-type="fig"}*B*,*E*) and variable durations of tens of seconds ([Fig. 1](#F1){ref-type="fig"}*B,F*). While there were no differences between the three groups (astrocyte soma, neuronal soma, and neuropil) with regards to the delay of the hypercapnia-induced Ca^2+^ responses (average Ca^2+^ response delay \[[Fig. 1](#F1){ref-type="fig"}*E*\]: neuron soma = 12.14 ± 1.19 s (*n* = 33), neuropil = 12.83 ± 4.18 s (*n* = 3), and astrocyte soma = 14.57 ± 1.55 s (*n* = 47)), the average Ca^2+^ response duration ([Fig. 1](#F1){ref-type="fig"}*F*) was found to be significantly longer in astrocytes than in neurons: neuron soma = 119.41 ± 8.82 s (*n* = 33), astrocyte soma = 155.47 ± 8.32 s (*n* = 47) (*p* \< 0.05, ANOVA).

![Astrocyte \[Ca^2+^\]~i~ transients are evoked by CO~2~ *in vivo*. ***A***, Example still images of mouse cortical layer II/III from 2PLSM. OGB is used as a calcium indicator (***Ai--Aiii***) and sulforhodamine 101 (SR101, ***Aiv***, average image for whole recording) is used to stain astrocytes. Color scale refers to images ***Ai--Aiii***. White arrows indicate astrocytes that show a Ca^2+^ response to CO~2~ of at least twice its baseline Ca^2+^ fluctuation. In this case, CO~2~ stimulus begins at *t* = 0 s and is applied for 36 s. ***Aiii***, Recovery of immediate CO~2~ induced Ca^2+^ transient. Scale bars, 40 μm. ***Bi***, ***Biii***, Further example images of mouse cortical layer II/III from 2PLSM showing example ROI placement. Merge images showing OGB and SR101 (***Bi***, ***Biii***). Red ROI1 indicates astrocyte endfoot. Red RO12 indicates astrocyte soma (layer II: *n* = 181, 8 mice). Green ROI indicates neuron soma (layer II: *n* = 153, 8 mice). Blue ROI indicates neuropil (layer II: *n* = 104, 8 mice). Scale bar, 20 μm. Example time series (***Bii***, ***Biv***) of \[Ca^2+^\]~i~ response in astrocyte and neuron soma ROIs (as indicated in ***Bi***, ***Biii***). Blue box represents time during which expired CO~2~ level is increased. ***C***, Mean Ca^2+^ response in ROIs. Colors represent ROIs located as shown in ***Bi***. ***D***, Percentage of ROIs for each cell type that showed a Ca^2+^ response with and without a hypercapnia stimulus. For no hypercapnia (control), *n* = 170 astrocyte somas, *n* = 148 neuronal soma, and *n* = 96 neuropil ROIs, *n* = 8 mice. Colors represent description in ***B***. ***E***, Delay from hypercapnia start time to start of Ca^2+^ response in ROI. ***F***, Duration of Ca^2+^ response in each ROI in response to CO~2~ stimulus. ***E***, ***F***, Box plots represent the mean (small square). Edges of the box represent 25% and 75% of data. End lines indicate maximum and minimum values. Data are mean ± SEM. \*\**p* \< 0.01. \*\*\**p* \< 0.001.](zns9991794720001){#F1}

Astrocytic \[Ca^2+^\]~i~ signals evoke subsequent GSH-dependent PgE~2~ release
------------------------------------------------------------------------------

Having demonstrated *in vivo* that hypercapnia evokes an increase in astrocyte \[Ca^2+^\]~i~, we then used a combination of 2PLSM and PgE~2~ measurements using ELISA in acute brain slices to determine the mechanistic links between astrocyte \[Ca^2+^\]~i~ responses and CBF regulation. Using a biochemical model, we investigated the role of GSH in the generation of PgE~2~.

Unlike in the *in vivo* situation, it is difficult to reliably evoke astrocyte \[Ca^2+^\]~i~ signals and vasodilations by applying CO~2~ to acute brain slices. Thus, we needed an alternative method of elevating astrocyte \[Ca^2+^\]~i~ in acute brain slices. Although the adult mouse ([@B42]) and rat ([@B10]) have been shown to not express functional mGluR5, bath application of the mGluR agonist tACPD is known to increase astrocyte \[Ca^2+^\]~i~ in younger animals ([@B24]). Therefore, tACPD was used to evoke reliable, reproducible astrocyte \[Ca^2+^\]~i~ elevations in acute brain slices from juvenile rats. To evoke widespread increases in astrocyte \[Ca^2+^\]~i~, hippocampal-neocortical slices were perfused with tACPD, an mGluR agonist. Application of tACPD (100 μ[m]{.smallcaps}) to brain slices (from juvenile rats) caused a generalized increase in astrocyte \[Ca^2+^\]~i~, observed using 2PLSM ([Fig. 2](#F2){ref-type="fig"}*A--C*), that provided us with the ability to measure subsequent synthesis of PgE~2~. Applying tACPD resulted in the formation and efflux of PgE~2~, as measured by ELISA ([Fig. 2](#F2){ref-type="fig"}*D*). The first step in the conversion of AA to PgE~2~ in astrocytes is via COX-1 ([Fig. 7](#F7){ref-type="fig"}) ([@B45]; [@B13]; [@B12]). Neurons, in contrast, express COX-2 but not COX-1 ([@B30]). In support of a central role for COX-1, we found that, although the tACPD-evoked increase in astrocyte \[Ca^2+^\]~i~ was unaltered ([Fig. 2](#F2){ref-type="fig"}*C*) in the presence of the COX-1 inhibitor SC560 ([@B41]; 100 n[m]{.smallcaps}: [@B4]), the resulting formation and efflux of PgE~2~, as measured by ELISA, was abolished (*p* \< 0.001; [Fig. 2](#F2){ref-type="fig"}*D*). Thus, astrocyte COX-1 activity is required for the subsequent PgE~2~ release in acute brain slices, which is triggered by astrocyte \[Ca^2+^\]~i~ signals.

![Astrocyte \[Ca^2+^\]~i~ signals evoke COX-1- and GSH-dependent vasodilations *in vitro*. ***A***, 2PLSM imaging: example Ca^2+^ and arteriole diameter changes in response to tACPD with and without BSO. Images represent overlay of pseudo-colored Ca^2+^ changes and transmitted light images. Dotted line indicates initial vessel diameter. Scale bar, 10 μm. ***B***, Mean time course of increase in astrocyte \[Ca^2+^\]~i~ in response to tACPD. Colored box represents time of tACPD application. Control, *n* = 56 from 26 rats; BSO, *n* = 39 from 18 rats. ***C***, Mean tACPD-evoked increase in astrocyte \[Ca^2+^\]~i~. tACPD, *n* = 56 from 26 rats; tACPD + SC560, *n* = 12 from 7 rats; tACPD + BSO, *n* = 39 from 18 rats. ***D***, Mean tACPD-evoked PgE~2~ release, measured by ELISA. Within a group, each experiment (*n*) uses tissue from a different rat (i.e., control, *n* = 8 from 8 rats). ***E***, Mean tissue GSH concentration; data from 4 rats for each group. ***F***, Mean time course of tACPD-evoked change in lumen diameter. Colored box represents time of tACPD application. Control, *n* = 31 slices from 26 rats; BSO, *n* = 21 slices from 18 rats. ***G***, Mean changes in lumen diameter evoked by tACPD and clonidine. tACPD, *n* = 31 slices from 26 rats; SC560 + tACPD, *n* = 7 slices from 7 rats; BSO + tACPD, *n* = 21 slices from 18 rats; clonidine, *n* = 8 slices from 8 rats; BSO + clonidine, *n* = 8 slices from 7 rats. ***H***, Mean changes in lumen diameter evoked by PgE~2~ and NE. PgE~2~, *n* = 5 slices from 4 rats; BSO + PgE~2~, *n* = 3 slices from 3 rats; NE, *n* = 14 slices from 11 rats; BSO + NE, *n* = 8 slices from 7 rats. Data are mean ± SEM. \*\**p* \< 0.01. \*\*\**p* \< 0.001. *n*, number of experiments conducted or, for calcium measurements, number of astrocyte ROIs analyzed.](zns9991794720002){#F2}

Downstream of COX-1 the synthesis of PgE~2~ involves the enzyme mPgES-1 ([@B44]), a form of prostaglandin E synthase expressed in astrocytes ([Fig. 3](#F3){ref-type="fig"}*A*) ([@B44]) that requires the cofactor GSH ([@B18]; [@B25]). It is known that GSH is present in high levels in astrocytes ([@B43]; [@B6]; [@B36]), as detected by staining of brain tissue with MCB, a GSH-sensitive dye ([Fig. 3](#F3){ref-type="fig"}*B*). Therefore, we investigated whether PgE~2~ formation was reduced when GSH levels were depressed. We examined whether there is a reduction in astrocyte \[Ca^2+^\]~i~-evoked PgE~2~ release in hippocampal slices after treatment with BSO (an inhibitor of γ-glutamylcysteine synthetase) for 2.5 h ([@B43]), which reduced the tissue GSH concentration by 27% (*p* = 0.009; [Fig. 2](#F2){ref-type="fig"}*E*). When GSH levels were decreased, although there was no change in basal PgE~2~ efflux ([Fig. 2](#F2){ref-type="fig"}*D*) or in the amplitude of tACPD-evoked astrocyte \[Ca^2+^\]~i~ signals ([Fig. 2](#F2){ref-type="fig"}*A--C*), strikingly the tACPD-evoked PgE~2~ efflux was reduced by 64% (*p* \< 0.001; [Fig. 2](#F2){ref-type="fig"}*D*).

![Astrocytes express mPGES-1 and contain high levels of GSH. ***A***, Immunohistochemistry showing astrocytic expression of GSH-dependent mPGES-1 in the CA3 of the hippocampus. Astrocyte marker, GFAP (red), mPGES-1 (green), and merge (yellow). Scale bar, 20 μm. ***B***, MCB-loaded hippocampal-neocortical slices. Astrocytes (identified by SR101, red, white arrowheads) contain higher levels of GSH (as indicated by MCB staining, green) than neurons (white arrows). Merge (yellow). Scale bar, 20 μm.](zns9991794720003){#F3}

Astrocyte \[Ca^2+^\]~i~ signals evoke COX-1 and GSH-dependent vasodilations in brain slices
-------------------------------------------------------------------------------------------

As COX-1 activity ([@B28]) and PgE~2~ release ([@B54]; [@B53]) have been shown to lead to increased CBF in response to hypercapnia, we examined whether COX-1-dependent PgE~2~ release evoked by astrocyte \[Ca^2+^\]~i~ signals triggered by either tACPD application or IP~3~ uncaging resulted in vasodilations.

Bath perfusion of tACPD induced arteriolar dilation in acute brain slices ([Fig. 2](#F2){ref-type="fig"}*A*,*F*,*G*), which was abolished in the presence of SC560 (*p* \< 0.01; [Fig. 2](#F2){ref-type="fig"}*G*), whereas the amplitude of evoked astrocyte \[Ca^2+^\]~i~ signals was unchanged (*p* \> 0.05; [Fig. 2](#F2){ref-type="fig"}*C*). Thus, combined with the results discussed above, these data confirm that astrocyte COX-1 activity and subsequent PgE~2~ release are required for vasodilations in acute brain slices that are triggered by astrocyte \[Ca^2+^\]~i~ signals.

As previously discussed, downstream of COX-1, the synthesis of PgE~2~ involves the astrocyte-expressed, GSH-dependent, enzyme mPgES-1 ([@B44]). Therefore, a role for astrocytes in the regulation of arteriole diameter would be supported if \[Ca^2+^\]~i~-evoked vasodilations were attenuated when GSH levels were depressed. We examined whether there is a reduction in subsequent vasodilations in hippocampal slices after treatment with BSO. When GSH levels were decreased, tACPD-evoked astrocyte \[Ca^2+^\]~i~ signals were unaltered ([Fig. 2](#F2){ref-type="fig"}*A--C*). However, the vasodilations triggered by these \[Ca^2+^\]~i~ signals were abolished ([Fig. 2](#F2){ref-type="fig"}*A*,*F*,*G*; *p* \< 0.01). Vasoconstrictions evoked by NE (100 μ[m]{.smallcaps}) or the α~2~ agonist clonidine (10 μ[m]{.smallcaps}), which act directly on arteriole smooth muscle cells ([@B7]), were unchanged in the presence of BSO ([Fig. 2](#F2){ref-type="fig"}*A*,*G*,*H*), indicating that arterioles were not damaged by the BSO treatment. Furthermore, BSO treatment did not alter the vasodilation evoked by either 1 μ[m]{.smallcaps} PgE~2~ ([Fig. 2](#F2){ref-type="fig"}*H*) or high \[K^+^\] (10 m[m]{.smallcaps}), which causes vasodilation by hyperpolarizing arteriole smooth muscle cells ([@B11]) (K^+^: 8.6 ± 2.3%, *n* = 5 slices from 5 rats; BSO + K^+^: 6.5 ± 0.8%, *n* = 6 slices from 3 rats, *p* = 0.37).

Astrocyte \[Ca^2+^\]~i~ increases can be triggered by two-photon uncaging of IP~3~ within the cell body of an astrocyte. Using this technique, we directly examined the effect of decreasing GSH levels on astrocyte \[Ca^2+^\]~i~-evoked arteriole dilations. Astrocytes in hippocampal slices from juvenile rats were bulk-loaded with the caged IP~3~ compound, NV-IP~3~/AM. Two-photon photolysis was used to uncage IP~3~ within an astrocyte soma specifically, generating a \[Ca^2+^\]~i~ increase within the soma, processes, and endfeet. This local increase in \[Ca^2+^\]~i~ could evoke an increase in \[Ca^2+^\]~i~ in nearby astrocytes ([Fig. 4](#F4){ref-type="fig"}*A*,*B* represents local and propagated responses) and elicited vasodilation of the neighboring arteriole ([Fig. 4](#F4){ref-type="fig"}*C*). Although astrocyte \[Ca^2+^\]~i~ signals were unaltered following BSO treatment to reduce GSH levels (*p* = 0.1; [Fig. 4](#F4){ref-type="fig"}*A*,*B*), dilations were not observed and vasoconstrictions were now evoked (*p* = 0.008; [Fig. 4](#F4){ref-type="fig"}*C*). Thus, when GSH levels are reduced, astrocyte \[Ca^2+^\]~i~ signals can no longer evoke vasodilations normally triggered by the release of PgE~2~.

![Astrocyte \[Ca^2+^\]~i~ transient-evoked vasodilations are GSH dependent *in vitro*. ***A***, Mean IP~3~-evoked increases in astrocyte \[Ca^2+^\]~i~. Control, *n* = 21 from 6 rats; +BSO, *n* = 11 from 4 rats. ***B***, Mean time course of increase in astrocyte \[Ca^2+^\]~i~. Dotted line indicates time of photolysis of caged IP~3~. *n* as described in ***A***. ***C***, Mean lumen diameter change in response to uncaging of IP~3.~ Uncage IP~3~, *n* = 11 slices from 6 rats; +BSO, *n* = 6 slices from 4 rats. Data are mean ± SEM. \*\**p* \< 0.01. *n*, number of experiments conducted or, for calcium measurements, number of astrocyte ROIs analyzed.](zns9991794720004){#F4}

*In vivo* hypercapnia-evoked CBF responses are GSH dependent
------------------------------------------------------------

Having determined in acute brain slices the vasodilatory molecules underlying astrocyte \[Ca^2+^\]~i~-evoked vasodilations, we examined whether these same enzymes and molecules were involved in the CBF response, which occurs downstream of CO~2~-evoked astrocyte \[Ca^2+^\]~i~ responses *in vivo*. Hypercapnia *in vivo* evoked a CBF increase in the barrel cortex of adult rat ([Fig. 5](#F5){ref-type="fig"}*A*,*B*,*D*,*E*), whereas neural activity was unchanged ([Fig. 5](#F5){ref-type="fig"}*F*). The calculated area under the curve (AUC) of the CBF response was significantly attenuated by SC560 (*p* = 0.032; [Fig. 5](#F5){ref-type="fig"}*A*,*B*), confirming that COX-1 plays a critical role in hypercapnia-evoked CBF increases *in vivo* ([@B28]).

![CO~2~ evoked CBF responses *in vivo* are GSH dependent. ***A***, Mean traces of local CBF response to hypercapnia, measured by laser speckle contrast imaging, in vehicle (DMSO)- (blue) and SC560- (red) injected animals. *n* = 7 rats for each group. Colored box represents time of CO~2~ application. Data shown as fractional change with baseline of 0 (baseline taken during 60 s prechallenge) and a pretreatment peak of 1 (black dotted line on graph). ***B***, Mean AUC of CBF response to hypercapnia in the presence of vehicle (DMSO) or SC560 (normalized to pretreatment maxima for each animal). *n* = 7 rats for each group. ***C***, Tissue GSH levels 24 h after injection of BSO or saline into the barrel cortex (*n* = 7 rats). ***D***, Mean trace of local CBF response to hypercapnia, measured by laser Doppler flowmetry, in saline- (blue) and BSO- (red) injected rats. *n* = 6 rats in each group. ***E***, Mean values of AUC of CBF response to hypercapnia. *n* = 6 rats in each group. ***F***, ***G***, Neural activity. Power in frequency bands. ***F***, During baseline (Base) and in response to hypercapnia (HCN) for saline- (blue) and BSO- (red) treated animals. *n* = 3 rats. ***G***, Hypercapnia (HCN)/baseline (Base). Treatment with BSO does not change the effect of hypercapnia on neural activity. *n* = 3 rats. Data are mean ± SEM. \* *p* \< 0.05.](zns9991794720005){#F5}

We examined the impact of decreased tissue GSH levels on CO~2~-evoked CBF increases *in vivo*. To lower GSH levels *in vivo*, BSO was injected into rat barrel cortex. After 24 h, tissue GSH levels in the ipsilateral cortex were reduced by 45% ([Fig. 5](#F5){ref-type="fig"}*C*; *p* = 0.018). Treatment with BSO reduced the hypercapnia-evoked CBF response ([Fig. 5](#F5){ref-type="fig"}*D,E*; AUC reduced by 65%, *p* = 0.048). Neural activity was no different in BSO-treated rats compared with saline-treated rats ([Fig. 5](#F5){ref-type="fig"}*G*). Combining all the data described so far suggests that hypercapnia-evoked, astrocyte \[Ca^2+^\]~i~-related, CBF increases require PgE~2~ release and, thus, are compromised when brain GSH levels are reduced.

This finding was specific to hypercapnia-evoked CBF increases. We examined the impact of decreased tissue GSH levels *in vivo* on functional hyperemia in the somatosensory cortex. Whisker pad stimulation (10 Hz) evoked a blood flow increase in the barrel cortex ([Fig. 6](#F6){ref-type="fig"}*A*). In agreement with previous findings ([@B27]), inhibiting COX-1 with SC560 had no effect on either the CBF response to whisker pad stimulation ([Fig. 6](#F6){ref-type="fig"}*A*,*B*; *p* = 0.10) or evoked neural activity (LFP) ([Fig. 6](#F6){ref-type="fig"}*C*; *p* = 0.91). Furthermore, the AUC of the stimulation-evoked CBF response was not significantly different in BSO-treated animals ([Fig. 6](#F6){ref-type="fig"}*D*; *p* = 0.14) compared with saline-treated animals, demonstrating that the CBF response is not GSH-sensitive. The magnitude of the neural response to whisker pad stimulation was unaffected by BSO ([Fig. 6](#F6){ref-type="fig"}*E*; *p* = 0.68). These results indicate that, under these experimental conditions, COX-1 and GSH play little, if any, role in the CBF response to somatosensory stimulation. These findings confirm that several different pathways exist that account for CBF regulation under differing conditions and in response to different stimuli.

![CBF responses to whisker pad stimulation *in vivo* are independent of GSH. ***A***, Mean time course of local CBF response to whisker pad stimulation, measured by laser speckle contrast imaging, in vehicle (DMSO)- (blue) and SC560- (red) injected rats. Colored box represents time of stimulation. Dotted black line indicates pretreatment peak of 1. ***B***, Mean AUC of the CBF response to whisker pad stimulation. *n* = 7 rats for each group. ***C***, Mean neural response (LFP) magnitude to whisker pad stimulus (summed over total 16 s length of stimulus). Responses are normalized to the first pulse response for each rat. *n* = 4 DMSO-treated rats; *n* = 3 SC560-treated rats. ***D***, Mean AUC of the whisker pad stimulation-evoked CBF response in saline- (blue) and BSO- (red) injected rats. *n* = 10 rats for each group. ***E***, Mean neural response (LFP) magnitude to whisker pad stimulation (summed over total 16 s length of stimulus). Responses are normalized to the first pulse response for each rat. *n* = 3 rats in each group. Data are mean ± SEM.](zns9991794720006){#F6}

Discussion
==========

We demonstrate a novel mechanism of CBF regulation involving astrocytes, which is GSH dependent. Previously, [@B28]) demonstrated that hypercapnia-evoked CBF increases are principally COX-1 dependent. In this study, we examined the mechanism of such CBF regulation, both upstream and downstream of hypercapnia-evoked increases in COX-1 activity ([Fig. 7](#F7){ref-type="fig"}). We demonstrate *in vivo* that, upstream of evoked COX-1 activity, CO~2~ increases \[Ca^2+^\]~i~ in astrocytes. These data demonstrate a new signal (hypercapnia) that activates astrocyte calcium and specifically identify the involvement of astrocytes in the regulation of CBF in response to changes in arterial CO~2~.

![Increases in astrocytic \[Ca^2+^\]~i~ may lead to GSH-dependent, PgE~2~-mediated vasodilation. Schematic diagram depicting how CO~2~-evoked increases in astrocytic \[Ca^2+^\]~i~ may lead to PgE~2~-mediated vasodilation. As a result of elevated \[Ca^2+^\]~i~, PLA~2~ is activated. PLA~2~ generates AA from the plasma membrane. AA can be processed locally by COX enzymes to produce AA derivatives, such as prostaglandin H~2~ (PgH~2~). PgE~2~ is produced from PgH~2~ by the enzyme PGEs, which requires GSH as a cofactor ([@B18]; [@B25]; [@B47]). PgE~2~ is released from astrocyte endfeet, which are apposed to the smooth muscle layer surrounding arterioles, resulting in activation of K^+^ channels, a decrease in Ca^2+^ entry into the smooth muscle cell and vasodilation.](zns9991794720007){#F7}

*In vitro*, using brain slices from juvenile animals in which it is possible to examine calcium signals by bulk loading a calcium indicator dye, we confirm that increased astrocyte \[Ca^2+^\]~i~ results in the subsequent release of PgE~2~ and vasodilation which are COX-1 activity-dependent ([Fig. 7](#F7){ref-type="fig"}). Our assumption that the evoked response in juvenile rat slices is the same as in adult rat with respect to COX-1 dependence is supported by the fact that the same COX-1 dependence has been shown in adult mice ([@B45]). We demonstrate that these findings hold *in vivo*, confirming previous findings in adult mice ([@B28]). Astrocytic endfeet, which are apposed to cerebral vascular smooth muscle, express all the machinery necessary for PgE~2~ synthesis (COX-1) ([@B45]; [@B13]), mPgES-1 ([Fig. 3](#F3){ref-type="fig"}*A*) ([@B44]), and GSH: ([Fig. 3](#F3){ref-type="fig"}*B*) ([@B43]; [@B6]; [@B36]), providing further evidence for the involvement of astrocytes in the regulation of CBF responses to hypercapnia. mPgES, an enzyme selectively expressed in astrocytes compared with neurons ([@B44]), is the enzyme responsible for producing PgE~2~ downstream of COX-1 activity. Intriguingly, the formation of PgE~2~ is regulated by the availability of GSH in astrocytes, as PgES requires GSH as a cofactor ([@B18]; [@B25]). *In vitro*, we demonstrate that astrocyte \[Ca^2+^\]~i~-evoked vasodilations are attenuated when GSH levels are depleted, whereas *in vivo*, we demonstrate that CO~2~-evoked CBF increases occur via a GSH-dependent mechanism. As astrocytes contain high levels of GSH ([Fig. 3](#F3){ref-type="fig"}*B*) ([@B43]; [@B6]; [@B36]), the dependence of the CO~2~-evoked CBF response on GSH is further evidence of astrocytic involvement. Together, our findings suggest a novel mechanism of astrocyte-evoked CBF regulation, which is GSH dependent. We propose that increased CO~2~ levels evoke \[Ca^2+^\]~i~ responses in astrocytes, subsequently activating a signaling pathway, involving COX-1 and the GSH-dependent PgES, which results in the release of the vasodilator PgE~2~. Thus, an increase in CO~2~ results in an astrocyte-driven, GSH-dependent vasodilation ([Fig. 7](#F7){ref-type="fig"}).

This GSH-dependent mechanism of CBF regulation exists alongside other COX-1 and GSH-insensitive mechanisms. For example, we found no effect of blocking COX-1 activity or of lowering GSH levels on CBF responses following 10 Hz whisker pad stimulation. Although it is possible that an astrocyte calcium response (and, thus, a GSH-sensitive mechanism of CBF regulation) may be evoked by an intense sensory stimulus ([@B38]; [@B39]), our results are in agreement with previous work suggesting that COX-1 is involved in CBF responses to hypercapnia ([@B28]) but not sensory stimulation ([@B27]). Although we saw no evidence that this pathway was important for functional (neuronal activity-evoked) increases in CBF under our experimental conditions, astrocytes appear to be an important intermediary for physiological (hypercapnia-evoked) increases in CBF. Our findings suggest that CBF regulation may involve astrocytes, and their \[Ca^2+^\]~i~ signals, under certain conditions and not under others.

Previous studies have provided evidence for several mechanisms linking astrocyte \[Ca^2+^\]~i,~ increases and changes in CO~2~ concentration. For example, within the respiratory center, increased astrocyte \[Ca^2+^\]~i,~ and astrocytic release of ATP can be triggered by CO~2~-evoked decreases in pH ([@B14]). This \[Ca^2+^\]~i,~ increase may be the result of increased Na^+^/HCO~3~^−^ cotransport and reversal of Na^+^/Ca^2+^ transport ([@B51]). It is unknown whether this mechanism also occurs within the cortex. Alternatively, increased CO~2~ can evoke hemichannel-mediated release of ATP ([@B17]), which may act on astrocytic purinergic receptors to elicit an increase in \[Ca^2+^\]~i~ ([@B33]). Depending on the mechanism linking increases in CO~2~ to astrocyte \[Ca^2+^\]~i~ responses, therefore, astrocytes could act as either a pH or CO~2~ sensor. Although it is beyond the scope of this paper to determine the link between an increase in CO~2~ and the increase in astrocyte \[Ca^2+^\]~i~, we have demonstrated that the depletion of GSH levels leads to a reduction in the ability of astrocytes to release PgE~2~ following such a rise in \[Ca^2+^\]~i,~ and so reduces their ability to evoke vasodilation in response to hypercapnia. This occurs because astrocytes express GSH-dependent mPgES-1.

Our finding that CBF responses to increased CO~2~ are GSH-sensitive suggests that global CBF regulation, which is sensitive to the partial pressure of arterial CO~2~ ([@B1]), will be affected in conditions where GSH levels are depleted. Alterations in the redox status of brain tissue that are ultimately linked to cellular GSH levels have been observed in numerous neurological and psychiatric disorders ([@B40]; [@B49], [@B50]; [@B2]; [@B55]; [@B19]). Therefore, the impact of changes in GSH levels on the sensitivity of astrocyte regulation of vasodilation could contribute to several CNS pathologies. Thus, it is critical to understand the signaling pathways underlying changes in CBF, both in health and disease.

It has previously been shown that, in addition to astrocytic production of PgE~2~ via COX-1/mPgES activity, neurons (which express COX-2 but not COX-1) ([@B30]; [@B22]), are capable of producing COX-2-derived PgE~2~ (which contributes to neurovascular coupling) ([@B22]; [@B20]). In this study, we used a pharmacological approach to increase astrocyte \[Ca^2+^\]~i~ and to inhibit either the *de novo* synthesis of glutathione or the activity of COX-1, specifically, to demonstrate that, downstream of an increase in astrocyte \[Ca^2+^\]~i~, COX-1 activity and glutathione are required for vasodilation to occur. However, as this pharmacological approach lacks cellular specificity, a contribution of neuronally produced PgE~2~ to the hypercapnia-evoked CBF response cannot be completely excluded. Nevertheless, our conclusion that astrocyte COX-1-derived PgE~2~, rather than neuronal COX-2-derived PgE~2~, is involved in the CBF response to hypercapnia is in agreement with previous findings ([@B28]). Future studies could use an astrocyte-specific genetic strategy (such as cell-specific knock-out) ([@B9]) to confirm that hypercapnia-evoked vasodilations, occurring downstream of astrocyte \[Ca^2+^\]~i~ responses, are dependent on astrocyte glutathione levels and COX-1 activity.

In conclusion, we demonstrate a novel mechanism by which astrocytes detect hypercapnia and, via \[Ca^2+^\]~i~ signals, increase CBF in response to CO~2~. Astrocytes are therefore poised to detect the metabolic activity of neurons and to modify vascular tone appropriately to deliver glucose and O~2~. This important pathway may be impaired in conditions in which oxidative stress reduces GSH levels in astrocytes, leading to impaired CBF responses and altered vascular readouts of neural activity.
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